支气管动脉化疗栓塞与静脉化学治疗中晚期肺癌的临床效果  

Curative effect of bronchial arterial chemoembolization and intravenous chemotherapy in the treatment of advanced lung cancer

作　　者：赖林强 涂建飞[1] 陈炜越 陈敏江[1] 纪建松[1] LAI Linqiang;TU Jianfei;CHEN Weiyue;CHEN Minjiang;JI Jiansong(Department of Intervention,Lishui Municipal Central Hospital(Fifth Affiliated Hospital of Wenzhou Medical University),Zhejiang Provincial Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research,Lishui,Zhejiang Province 323000,China)

机构地区：[1]丽水市中心医院(温州医科大学附属第五医院)介入科,浙江省影像诊断与介入微创研究重点实验室,浙江丽水323000

出　　处：《介入放射学杂志》2023年第3期233-236,共4页Journal of Interventional Radiology

基　　金：国家卫生健康委员会,浙江省医药卫生重大科技计划重点项目(WKJ-ZJ-1932)。

摘　　要：目的 探讨载药微球支气管动脉化疗栓塞(DEB-BACE)和单纯全身静脉化学治疗中晚期肺癌的疗效和无进展生存差异。方法 选择2018年8月至2021年8月丽水市中心医院收治的中晚期肺癌患者80例,其中DEB-BACE组40例,静脉化疗组40例。定期跟踪随访,收集临床资料。两组患者的疾病控制率(DCR)和客观缓解率(ORR)比较采用χ^(2)检验,两组患者的生存情况比较采用生存曲线和Log-rank检验。结果 两组患者的临床资料中,除既往治疗情况和转移灶数目差异有统计学意义(P<0.05)外,其余指标差异均无统计学意义(P>0.05)。DEB-BACE组中位随访时间为14.0个月,化疗组中位随访时间为20.5个月,差异无统计学意义(Z=-0.732,P=0.464)。DEB-BACE组的DCR为67.5%,优于化疗组的42.5%,差异有统计学意义(χ^(2)=5.051,P=0.025);DEB-BACE组ORR也优于化疗组(χ^(2)=11.665,P=0.002)。DEB-BACE组中位无进展生存时间(mPFS)为8.0个月,化疗组为3.0个月。DEB-BACE组6、12和24个月无进展生存率分别为67.5%、34.0%和3.2%,化疗组分别为30.0%、15.0%和7.5%,差异有统计学意义(χ^(2)=6.028,P=0.014)。结论 DEB-BACE组的DCR、ORR、mPFS均高于化疗组,表明DEB-BACE在中晚期肺癌治疗方面具有重要的应用前景。Objective To compare the curative effect and progression-free survival between drugeluting beads bronchial artery chemoembolization(DEB-BACE)and systemic intravenous chemotherapy alone in the treatment of advanced lung cancer.Methods A total of 80 patients with advanced lung cancer,who were admitted to the Lishui Municipal Central Hospital of China between August 2018 and August 2021,were collected.The patients were randomly and equally divided into DEB-BACE group(n=40)and intravenous chemotherapy group(chemotherapy group,n=40).The patients were regularly followed up and the clinical data were collected.The χ^(2) test was used to compare the disease control rate(DCR)and objective response rate(ORR)of the two groups,and the survival curve and Log-rank test were used to compare the survival of the two groups.Results The differences in the previous treatment status and the number of metastases between the two groups were statistically significant(P<0.05),while the differences in the other clinical indexes between the two groups were not statistically significant(P>0.05).The median follow-up time of DEB-BACE group was 14.0 months,which was 20.5 months in the chemotherapy group,the difference between the two groups was not statistically significant(Z=-0.732,P-0.464).The DCR in the DEB-BACE group was 67.5%,which was higher than 42.5%in the chemotherapy group,the difference between the two groups was statistically significant(χ^(2)=-5.051,P-0.025).The ORR in the DEB-BACE group was better than that in the chemotherapy group(χ^(2)=11.665,P-0.002).The median progression-free survival(mPFS)in the DEB-BACE group was 8.0 months,which was 3.0 months in the chemotherapy group.The 6-month,12-month and 24-month progression-free survival rates in the DEB-BACE group were 67.5%,34.0%and 3.2%respectively,which in the chemotherapy group were 30.0%,15.0%and 7.5%respectively,and the differences were statistically significant(χ^(2)=6.028,P=0.014).Conclusion The DCR,ORR and mPFS in the DEB-BACE group are better than those in the chemo

关 键 词：中晚期肺癌 载药微球 支气管动脉化疗栓塞 化疗 

分 类 号：R734.2[医药卫生—肿瘤]